CMS von Erlach Partners Ltd. houses a broad offering which notably acts for Bayer, Eli Lilly, and Unilabs, often leveraging its international network of offices. The team also handles advertising-focused proceedings and cross-border acquisitions. Team co-leads Patrick Sommer routinely advises on M&A and administrative proceedings concerning antitrust pricing issues, and Christoph Willi is well-equipped to handle series financing matters and patent portfolio management mandates.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Oversight, diligence, excellent business acumen.’
‘International network which allows quick access to lawyers based in other jurisdictions.’
‘Very skilled people, highly reactive and to the point.’
'Christoph Willi: Fast response times, puts the customer at the centre.'
Key clients
- Bayer (Switzerland) AG
- Syncona Ltd
- Medbase AG
- Unilabs AG
- Vista Klinik Holding AG
- Eli Lilly (Suisse) S.A
- Lilly Deutschland GmbH
- Ypsomed AG
Work highlights
Advised Vista Klinik Holding AG on the acquisition of ophthalmological service providers and related regulatory questions.
Advised Ypsomed AG on the sale of its pen needle and blood glucose monitoring system business with reported sales of CHF 52 million in 2022/2023.
Acted in arbitration proceedings for a Swiss-American pharmaceutical manufacturer against a clinical developer concerning an innovative drug candidate for the treatment of haematological malignancies.
Lawyers
Practice head
Patrick Sommer; Christoph Willi
Other key lawyers
Alain Raemy; Simone Brauchbar Birkhäuser; Julia Haas